SCHEMBL4467724

SCHEMBL4467724

CNc1nccc(Oc2ccc(NC(=O)O)cc2)c1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 8/20 0.46
KDR P35968 7/20 0.46
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MYOC Q99972 1/20 0.41
GAA P10253 2/20 0.41
PKM P14618 1/20 0.41
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
KIT P10721 1/20 0.39
RAF1 P04049 1/20 0.39
F13A1 P00488 1/20 0.38
POLB P06746 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467713 1.00 PDGFRA (0.46) PDGFRAKDRMEN1KMT2AMAPT
SCHEMBL4466297 0.86 PRMT1 (0.49) PDGFRAKDRMEN1KMT2AMAPT
SCHEMBL2937186 0.83 PDGFRA (0.45) PDGFRAKDRMEN1KMT2AMAPT
SCHEMBL2937189 0.83 PDGFRA (0.45) PDGFRAKDRMEN1KMT2AMAPT
SCHEMBL2311116 0.83 KDR (0.44) PDGFRAKDRKIT
SCHEMBL2311104 0.83 KDR (0.44) PDGFRAKDRKIT
SCHEMBL2311112 0.81 PDGFRA (0.36) PDGFRAKDRMEN1KMT2AMAPT
SCHEMBL4454565 0.81 PDGFRA (0.43) PDGFRAKDRNPC1RAB9AKIT
SCHEMBL13603235 0.79 PRMT1 (0.51) PDGFRAKDRMEN1KMT2AMAPT
SCHEMBL2315672 0.75 PDGFRA (0.33) PDGFRAKDRMAPTNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812433-B1 IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS CANCER REC TECH LTD (GB) 2015-07-22 EP disclosed
US-7625922-B2 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-01 US disclosed
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-13 US disclosed
EP-1812433-A1 IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS Cancer Research Technology Limited (GB) 2007-08-01 EP disclosed
WO-2006043090-A1 IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds NR2E1, NR0B1, BRAF PDGFRA 1561/4885KDR 167/4885MEN1 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.